SNY Jan 2025 45.000 call
| Previous close | 6.00 |
| Open | 6.00 |
| Bid | 3.10 |
| Ask | 7.60 |
| Strike | 45.00 |
| Expiry date | 2025-01-17 |
| Day's range | 6.00 - 6.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
ZacksKymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.
- Reuters
UPDATE 2-US urges makers of infant RSV shots to meet winter demand
U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week. The officials on Tuesday met with representatives of Sanofi , AstraZeneca and Thermo Fisher "and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market," the White House said in a statement.
ZacksSanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
